|
시장보고서
상품코드
1545622
세계의 생체 전기 의학 시장 : 유형별, 제품별, 용도별, 최종 사용자별, 지역별 예측(-2030년)Global Bioelectric Medicine Market Research Report Information by Type, by Product, By Application, By End User, By Region - Forecast till 2030 |
||||||
생체 전기 의학 시장 규모는 예측 기간 동안 6.53%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예측됩니다.
생체 전기 의학 산업은 세계적인 만성질환의 유병률 상승과 진입사업자의 전략적 이니셔티브 증가에 의해 견인되고 있습니다. 세계보건기구에 따르면 2019년에는 1,800만 명이 류마티스 관절염을 앓고 있으며, 그 70%가 여성이고 55%가 55세 이상으로 되어 있습니다. 또한 Crohn's & Colitis UK는 2022년까지 영국 123명 중 1명이 크론병 또는 궤양성 대장염을 앓고 있다고 추정합니다. 고비용 생체 전기 의학 기기가 시장 성장을 방해할 우려가 있지만, 그럼에도 불구하고 진입기업의 임상시험 확대와 투자 증가가 업계에 유익한 전망을 가져올 것으로 기대되고 있습니다.
지역별 인사이트
북미 시장은 2022년에 38.01%에서 가장 큰 시장 점유율을 차지했으며, 예측 기간 중에는 4.71%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 2030년에는 약 160억 달러 규모에 달할 것으로 예측됩니다. 또한 아시아태평양은 예측 기간 동안 CAGR 8.99%에서 가장 높은 성장률을 보일 것으로 예상됩니다.
북미의 생체 전기 의학 시장의 미래는 여전히 밝고 지속적인 확대가 기대되고 있습니다. 의료 인프라에 대한 투자와 최신 의료 솔루션의 인지도 향상은 시장 성장을 더욱 촉진할 것으로 예상됩니다. 기존 기업과 신규 진출기업 모두 보다 나은 수술 결과에 대한 요구의 고조에 대응하기 위해 기술적 개선을 활용하여 이러한 가능성을 파악할 준비가 되어 있습니다.
유럽 시장은 기술 개선, 의료비 상승, 만성 질환 유병률 증가로 2위 시장 점유율을 차지했습니다. 게다가 독일의 생체 전기 의학 시장이 가장 큰 시장 점유율을 갖고 있으며, 프랑스의 생체 전기 의학 시장은 유럽에서 가장 빠르게 확대될 것으로 예측됩니다.
아시아태평양 시장은 환자 인구의 많음, 만성 질환의 유병률 증가 및 유리한 규제 정책에 따라 2023년에서 2032년 사이에 가장 빠르게 발전할 것으로 예측됩니다. 또, 대기업이 이 지역에 끊임없이 진출하고 있어 지역 시장의 성장을 가속시키고 있습니다. 중국이 가장 큰 점유율을 차지하고 인도는 가장 빠르게 성장하는 시장이 될 전망입니다.
이 보고서는 세계의 생체 전기 의학 시장을 조사했으며, 시장 정의 및 개요, 시장 성장에 대한 각종 영향요인 분석, 시장 규모 추이 및 예측, 각종 구분 및 지역별 분석, 경쟁 환경, 주요 기업 프로파일 등을 정리했습니다.
목차
제1장 주요 요약
제2장 시장 개요
제3장 조사 방법
제4장 시장 역학
- 개요
- 성장 촉진요인
- 세계에서 만성질환의 발생 증가
- 참가 기업에 의한 전략적 이니셔티브 고조
- 억제요인
- 생체 전기 의학 기기와 관련된 높은 비용
- 기회
- 생체 전기 의학의 임상시험 증가
- 진입기업에 의한 생체 전기 의학 투자 증가
제5장 시장 요인 분석
- Porter's Five Forces 분석
- COVID-19가 시장에 미치는 영향
제6장 세계의 생체전기 의료 시장 : 제품별
- 이식형 제세동기
- 심장 페이스메이커
- 인공 내이
- 척수 자극 장치
- 뇌심부 자극 장치
- 경피 전기 신경 자극 장치
- 천골 신경 자극 장치
- 미주 신경 자극 장치
- 기타
제7장 세계의 생체전기 의료시장 : 유형별
- 임베디드 전기 치료 장치
- 비침습성 전기 치료 장치
제8장 세계의 생체전기 의료 시장 : 용도별
- 부정맥
- 통증 관리
- 감음 난청
- 파킨슨병
- 떨림
- 우울
- 간질
- 요실금 및 변실금
- 기타
제9장 세계 생체전기 의료시장 : 최종 사용자별
- 병원
- 연구기관
- 기타
제10장 세계의 생체전기 의료시장 : 지역별
- 개요
- 북미
- 유럽
- 아시아태평양
- 기타 지역
제11장 경쟁 구도
- 개발 건수로 톱의 기업
- 주요 전개 및 성장 전략
- 주요 기업의 재무 매트릭스
제12장 기업 프로파일
- ABBOTT
- BOSTON SCIENTIFIC CORPORATION
- ALEVA NEUROTHERAPEUTICS
- COCHLEAR LTD.
- LIVANOVA PLC
- MEDTRONIC
- BIOTRONIK
- CHARCO NEUROTECH
- NEVRO CORP
- ELECTROCORE, INC
제13장 부록
AJY 24.09.12Global Bioelectric Medicine Market Research Report Information by Type (Implantable Electroceutical Devices and Non-invasive Electroceutical Devices), by Product (Implantable Cardioverter Defibrillators, Cardiac Pacemakers, Cochlear Implants, Spinal Cord Stimulators, Deep Brain Stimulators, Transcutaneous Electrical Nerve Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators, And Others), By Application (Arrhythmia, Pain Management, Sensorineural Hearing Loss, Epilepsy, And Others), By End User (Hospitals & Clinics, ASCs, and Others), By Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2030
Market Overview
The Bioelectric Medicine Market is expected to expand at a compound annual growth rate (CAGR) of 6.53% over the projected period. The Bioelectric Medicine industry is being driven by rising prevalence of chronic diseases around the world, as well as increased strategic initiatives by industry participants. According to the World Health Organization, 18 million individuals suffered from rheumatoid arthritis in 2019, with 70% of them being women and 55% being over the age of 55. Furthermore, Crohn's & Colitis UK estimated that one in every 123 persons in the UK will have Crohn's disease or ulcerative colitis by 2022. However, the high cost of bioelectric medical devices is projected to hinder global market growth. Nonetheless, expanding clinical trials for bioelectric medicine and increased investment in bioelectric medicine by market participants are expected to generate profitable prospects for the industry.
The increasing prevalence of chronic diseases around the world is considerably contributing to the expansion of bioelectric medicine. Chronic diseases, including chronic pain conditions, neurological disorders, inflammatory diseases, and metabolic disorders, place a significant strain on healthcare systems and have a negative influence on patients' quality of life. Traditional treatment approaches, such as medicines and surgery, may have limited success or carry concerns of side effects for some people. The increasing prevalence of disorders, together with bioelectric medicine's prospective applicability in these circumstances, is driving up demand for bioelectric medicine products. For example, deep brain stimulation (DBS) has been proven to be effective in treating Parkinson's disease symptoms by regulating aberrant neural activity. Similarly, neuromodulation devices such as vagus nerve stimulation (VNS) have showed efficacy in lowering seizure frequency in epilepsy patients. Furthermore, in February 2024, the World Health Organization stated that approximately 50 million individuals worldwide suffer from epilepsy, with nearly 80% living in low- and middle-income nations.
Market Segment insights
Product-wise, the global bioelectric medicine segment includes implantable cardioverter defibrillators, cardiac pacemakers, cochlear implants, spinal cord stimulators, deep brain stimulators, transcutaneous electrical nerve stimulators, sacral nerve stimulators, vagus nerve stimulators, and others.
The bioelectric medicine market is divided into two types: implanted electroceutical devices and noninvasive electroceutical devices.
The Bioelectric Medicine Market has been categorized by application, including arrhythmia, pain management, sensorineural hearing loss, Parkinson's disease, tremor, depression, epilepsy, urine and fecal incontinence, among others.
The market is divided into three segments based on the end user: hospitals, research institutes, and others.
Regional insights
The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. North America's bioelectric medicine market held the greatest market share of 38.01% in 2022 and is expected to reach roughly USD 16.00 billion by 2030, growing at a 4.71% CAGR during the forecast period. However, Asia-Pacific is expected to develop at the fastest CAGR of 8.99% over the forecast period.
The future for the North American bioelectric medicine market remains positive, with continued expansion expected. Investments in healthcare infrastructure and increased awareness of modern medical solutions are projected to propel market growth even further. Both established firms and new entrants are ready to seize these possibilities, utilizing technological improvements to address the growing need for better surgical outcomes.
Europe's bioelectric medicine market accounted for the second-largest market share due to technological improvements, rising healthcare costs, and an increase in the prevalence of chronic conditions. Furthermore, the Germany bioelectric medicine market is expected to have the greatest market share, with France's bioelectric medicine market forecast to be the fastest expanding market in Europe.
The Asia-Pacific bioelectric medicine market is predicted to develop the fastest between 2023 and 2032 due to its large patient population, increased prevalence of chronic diseases, and favorable regulatory policies. Furthermore, prominent market companies are constantly expanding into this region, accelerating regional market growth. Furthermore, China's bioelectric medicine market held the greatest market share, while India's bioelectric medicine market is expected to be the fastest expanding market in the Asia-Pacific region.
Major Players
Abbott (US), Boston Scientific Corporation (US), Bortnick (Germany), Aleva Neurotherapeutics (Switzerland), Cochlear Ltd. (Australia), LivaNova PLC (UK), Medtronic (Ireland), Charco Neurotech (UK), ElectroCore, Inc. (US), and Nevro Corp (US) are some of the key companies in the Bioelectric Medicine market.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
- 1.1 OVERVIEW
2 MARKET INTRODUCTION
- 2.1 DEFINITION
- 2.2 SCOPE OF THE STUDY
- 2.3 RESEARCH OBJECTIVE
- 2.4 MARKET STRUCTURE
- 2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
- 3.1 DATA MINING
- 3.2 SECONDARY RESEARCH
- 3.3 PRIMARY RESEARCH
- 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
- 3.5 FORECASTING TECHNIQUES
- 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
- 3.7 DATA TRIANGULATION
- 3.8 VALIDATION
4 MARKET DYNAMICS
- 4.1 OVERVIEW
- 4.2 DRIVERS
- 4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES ACROSS THE GLOBE
- 4.2.2 RISING STRATEGIC INITIATIVES BY MARKET PLAYERS
- 4.3 RESTRAINTS
- 4.3.1 HIGH COST ASSOCIATED WITH BIOELECTRIC MEDICINE DEVICES
- 4.4 OPPORTUNITIES
- 4.4.1 INCREASING CLINICAL TRIALS FOR BIOELECTRIC MEDICINE
- 4.4.2 RISING INVESTMENT IN BIOELECTRIC MEDICINE BY MARKET PLAYERS
5 MARKET FACTOR ANALYSIS
- 5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
- 5.2 IMPACT OF COVID-19 ON THE GLOBAL BIOELECTRIC MEDICINE MARKET
6 GLOBAL BIOELECTRIC MEDICINE MARKET, BY PRODUCT
- 6.1 OVERVIEW
- 6.1.1 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS
- 6.1.2 CARDIAC PACEMAKERS
- 6.1.3 COCHLEAR IMPLANTS
- 6.1.4 SPINAL CORD STIMULATORS
- 6.1.5 DEEP BRAIN STIMULATORS
- 6.1.6 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATORS
- 6.1.7 SACRAL NERVE STIMULATORS
- 6.1.8 VAGUS NERVE STIMULATORS
- 6.1.9 OTHERS
7 GLOBAL BIOELECTRIC MEDICINE MARKET, BY TYPE
- 7.1 OVERVIEW
- 7.1.1 IMPLANTABLE ELECTROCEUTICAL DEVICES
- 7.1.2 NON-INVASIVE ELECTROCEUTICAL DEVICES
8 GLOBAL BIOELECTRIC MEDICINE MARKET, BY APPLICATION
- 8.1 OVERVIEW
- 8.1.1 ARRHYTHMIA
- 8.1.2 PAIN MANAGEMENT
- 8.1.3 SENSORINEURAL HEARING LOSS
- 8.1.4 PARKINSON'S DISEASE
- 8.1.5 TREMOR
- 8.1.6 DEPRESSION
- 8.1.7 EPILEPSY
- 8.1.8 URINARY AND FECAL INCONTINENCE
- 8.1.9 OTHERS
9 GLOBAL BIOELECTRIC MEDICINE MARKET, BY END USER
- 9.1 OVERVIEW
- 9.1.1 HOSPITALS
- 9.1.2 RESEARCH INSTITUTES
- 9.1.3 OTHERS
10 GLOBAL BIOELECTRIC MEDICINE MARKET, BY REGION
- 10.1 OVERVIEW
- 10.2 NORTH AMERICA
- 10.2.1 US
- 10.2.2 CANADA
- 10.3 EUROPE
- 10.3.1 GERMANY
- 10.3.2 FRANCE
- 10.3.3 UK
- 10.3.4 ITALY
- 10.3.5 SPAIN
- 10.3.6 REST OF EUROPE
- 10.4 ASIA-PACIFIC
- 10.4.1 CHINA
- 10.4.2 INDIA
- 10.4.3 JAPAN
- 10.4.4 AUSTRALIA
- 10.4.5 SOUTH KOREA
- 10.4.6 REST OF ASIA-PACIFIC
- 10.5 REST OF THE WORLD
- 10.5.1 MIDDLE EAST
- 10.5.2 AFRICA
- 10.5.3 LATIN AMERICA
- 11.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL BIOELECTRIC MEDICINE MARKET
- 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.6.1 PRODUCT LAUNCH
- 11.6.2 PRODUCT APPROVAL
- 11.6.3 ACQUISITION
- 11.6.4 INVESTMENT
- 11.6.5 EXPANSION
- 11.7 MAJOR PLAYERS FINANCIAL MATRIX
- 11.7.1 SALES (USD BILLION),
- 11.7.2 R&D (USD BILLION),
12 COMPANY PROFILES
- 12.1 ABBOTT
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL ANALYSIS
- 12.1.3 PRODUCTS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
- 12.2 BOSTON SCIENTIFIC CORPORATION
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 PRODUCTS OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGIES
- 12.3 ALEVA NEUROTHERAPEUTICS
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 PRODUCT OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 KEY STRATEGIES
- 12.4 COCHLEAR LTD.
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 SWOT ANALYSIS
- 12.4.6 KEY STRATEGIES
- 12.5 LIVANOVA PLC
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 KEY STRATEGIES
- 12.6 MEDTRONIC
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 SWOT ANALYSIS
- 12.6.6 KEY STRATEGIES
- 12.7 BIOTRONIK
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 KEY STRATEGIES
- 12.8 CHARCO NEUROTECH
- 12.8.1 COMPANY OVERVIEWS
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 KEY STRATEGIES
- 12.9 NEVRO CORP
- 12.9.1 COMPANY OVERVIEWS
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
- 12.10 ELECTROCORE, INC
- 12.10.1 COMPANY OVERVIEWS
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 SWOT ANALYSIS
- 12.10.6 KEY STRATEGIES
13 APPENDIX
- 13.1 REFERENCES
- 13.2 INTERNATIONAL ASSOCIATION FOR THE STUDY OF PAIN
- 13.3 AMERICAN PARKINSON DISEASE ASSOCIATION
- 13.4 PARKINSON'S FOUNDATION
- 13.5 ANXIETY AND DEPRESSION ASSOCIATION OF AMERICA
- 13.6 EUROPEAN ALLIANCE AGAINST DEPRESSION
- 13.7 AMERICAN SOCIETY OF INTERVENTIONAL PAIN PHYSICIANS
- 13.8 THE AFRICAN SOCIETY FOR REGIONAL ANESTHESIA (AFSRA)
- 13.9 DEEP BRAIN STIMULATION NURSE ASSOCIATION (DBSNA)
- 13.10 EUROPEAN SOCIETY OF CARDIOLOGY
- 13.11 THE COCHLEAR IMPLANT GROUP OF INDIA
- 13.12 AMERICAN COCHLEAR IMPLANT ALLIANCE
- 13.13 UNITED SPINAL ASSOCIATION
- 13.14 AMERICAN SPINAL INJURY ASSOCIATION
- 13.15 NATIONAL SPINAL CORD INJURY ASSOCIATION
- 13.16 AMERICAN CLINICAL NEUROPHYSIOLOGY SOCIETY.
- 13.17 EUROPEAN ACADEMY OF NEUROLOGY (EAN)
- 13.18 CHILD NEUROLOGY SOCIETY.
- 13.19 AUSTRALIA EPILEPSY SOCIETY
- 13.20 RELATED REPORTS
